Adalvo has progressed into the pilot BE study phase for Apalutamide, with results expected by June 2025, marking a key step towards submission and Day 1 launch readiness in major markets.
Based on the reference brand Erleada, Apalutamide is an oral treatment available in 60mg and 240mg film-coated tablets, used in the management of non-metastatic castration-resistant prostate cancer (nmCRPC) and metastatic hormone-sensitive prostate cancer (mHSPC). These conditions represent a growing therapeutic area with high clinical relevance and patient need.
The product recorded global MAT sales of $4 billion in 2024, with a 36% 3Y CAGR (IQVIA), reflecting sustained commercial growth and market relevance.
Adalvo’s program is supported by a clear regulatory strategy and a focused development plan, reinforcing its commitment to first-to-market execution in high-value therapeutic categories.
By accelerating the development of complex oncology generics like Apalutamide, Adalvo strengthens its position as a partner of choice for science-driven, strategically aligned product launches.
Get in touch today!